Health & Fitness
Health and Fitness
Health and Fitness
Thu, March 14, 2013
Wed, March 13, 2013
Tue, March 12, 2013
Lpath to Present at ROTH Capital Partners 25th Annual Growth Stock Conference on March 19, 2013
March 12, 2013 08:31 ET
Lpath to Present at ROTH Capital Partners 25th Annual Growth Stock Conference on March 19, 2013
SAN DIEGO, CA--(Marketwire - Mar 12, 2013) - Lpath, Inc. (
Lpath President and CEO Scott Pancoast is scheduled to present on Tuesday, March 19, 2013 at 1:00 p.m. Pacific time, with one-on-one meetings held throughout the day. He will discuss the company's pathway to regulatory approval and commercialization of its novel lipidomics-based therapeutics, as well as its ability to attract support from financial and strategic partners such as Pfizer, J&J, Biogen Idec, and Merck-Serono, as well as the NIH and the Department of Defense.
The presentation will be webcast live at [ http://www.wsw.com/webcast/roth27/lptn/ ], which will be available for replay in the investor relations section at [ www.lpath.com ].
For more information about the conference or to schedule a one-on-one meeting with Lpath management, please contact your ROTH representative at 1-800-933-6830 or via e-mail at [ oneononerequests@roth.com ].
About ROTH Capital Partners
ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. and Hong Kong. For more information on ROTH, please visit [ www.roth.com ].
About Lpath
San Diego-based Lpath, Inc., a therapeutic antibody company, is the category leader in lipid-targeted therapeutics. The company's ImmuneY2™ drug-discovery engine has the unique ability to generate monoclonal antibodies that bind to and inhibit bioactive lipids that contribute to disease. The company is developing three drug candidates: iSONEP™ is in a Phase 2 trial for wet AMD; ASONEP™ is in a Phase 2 trial in Renal Cell Carcinoma patients; and Lpathomab is a preclinical drug candidate that holds promise in pain, neurotrauma, and other diseases.
